Literature DB >> 33785584

Epidemiology and prognostic factors of pleural empyema.

Antonio Bobbio1, Samir Bouam2, Jerome Frenkiel3, Kevin Zarca4, Ludovic Fournel5,6, Emelyne Canny5, Philippe Icard5, Raphaël Porcher7, Marco Alifano5,6.   

Abstract

BACKGROUND: Infection of the pleural cavity invariably leads to hospitalisation, and a fatal outcome is not uncommon. Our aim was to study the epidemiology of pleural empyema on a nationwide basis in the whole population and in three subgroups of patients, namely post-lung resection, associated cancer and those with no surgery and no cancer.
METHODS: Data from patients aged ≥18 years hospitalised with a diagnosis of pleural infection in France between January 2013 and December 2017 were retrieved from the medical-administrative national hospitalisation database and retrospectively analysed. Mortality, length of stay and costs were assessed.
RESULTS: There were 25 512 hospitalisations for pleural empyema. The annual rate was 7.15 cases per 100 000 habitants in 2013 and increased to 7.75 cases per 100 000 inhabitants in 2017. The mean age of patients was 62.4±15.6 years and 71.7% were men. Post-lung resection, associated cancer and no surgery-no cancer cases accounted for 9.8%, 30.1% and 60.1% of patients, respectively. These groups were significantly different in terms of clinical characteristics, mortality and risk factors for length of stay, costs and mortality. Mortality was 17.1% in the whole population, 29.5% in the associated cancer group, 17.7% in the post-lung resection group and 10.7% in the no surgery-no cancer group. In the whole population, age, presence of fistula, higher Charlson Comorbidity Index (>3), alcohol abuse, arterial hypertension, hyperlipidaemia, atheroma, atrial fibrillation, performance status >3 and three subgroups of pleural empyema independently predicted mortality.
CONCLUSIONS: Empyema is increasing in incidence. Factors associated with mortality are recent lung resection and associated diagnosis of cancer. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical epidemiology; empyema; pleural disease

Mesh:

Year:  2021        PMID: 33785584     DOI: 10.1136/thoraxjnl-2020-215267

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  Clinical Application and Evaluation of Metagenomic Next-Generation Sequencing in Pulmonary Infection with Pleural Effusion.

Authors:  Huifen Xu; Xiaoman Hu; Wenyu Wang; Hong Chen; Fangfei Yu; Xiaofei Zhang; Weili Zheng; Kaiyu Han
Journal:  Infect Drug Resist       Date:  2022-06-01       Impact factor: 4.177

2.  The impact of the COVID-19 pandemic on pleural infection incidence: a UK multicentre retrospective analysis.

Authors:  Eihab O Bedawi; Khalil Ur Rehman; Deepan P Sivakumar; Katie Ferguson; Syed Ajmal; Emma Graham; Rakesh K Panchal; John P Corcoran; Kevin G Blyth; Najib M Rahman; Alex West
Journal:  ERJ Open Res       Date:  2022-08-01

Review 3.  Recent Insights into the Management of Pleural Infection.

Authors:  Maged Hassan; Shefaly Patel; Ahmed S Sadaka; Eihab O Bedawi; John P Corcoran; José M Porcel
Journal:  Int J Gen Med       Date:  2021-07-14

4.  Pleural empyema secondary to nephropleural fistula in complicated pyonephrosis.

Authors:  Stefania Tamburrini; Marina Lugarà; Pietro Paolo Saturnino; Giovanni Ferrandino; Pasquale Quassone; Silvio Leboffe; Giuseppe Sarti; Concetta Rocco; Claudio Panico; Francesco Raffaele; Teresa Cesarano; Michele Iannuzzi; Lucio Cagini; Ines Marano
Journal:  Radiol Case Rep       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.